tbuckley/cabot-search huggingface dataset:
Introduction of Nature's Complexity in Engineered Blood‐compatible Biomaterials
Authors: Bastiaan D. Ippel, Patricia Y. W. Dankers
Journal: Advanced Healthcare Materials (2017)

Abstract Biomaterials with excellent blood‐compatibility are needed for applications in vascular replacement therapies, such as vascular grafts, heart valves and stents, and in extracorporeal devices such as hemodialysis machines and blood‐storage bags. The modification of materials that are being used for blood‐contacting devices has advanced from passive surface modifications to the design of more complex, smart biomaterials that respond to relevant stimuli from blood to counteract coagulation. Logically, the main source of inspiration for the design of new biomaterials has been the endogenous endothelium. Endothelial regulation of hemostasis is complex and involves a delicate interplay of structural components and feedback mechanisms. Thus, challenges to develop new strategies for blood‐compatible biomaterials now lie in incorporating true feedback controlled mechanisms that can regulate blood compatibility in a dynamic way. Here, supramolecular material systems are highlighted as they provide a promising platform to introduce dynamic reciprocity, due to their inherent dynamic nature.
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m<sup>2</sup>) and the Currently Approved Dose (25 mg/m<sup>2</sup>) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA
Authors: Mario Eisenberger, Anne-Claire Hardy-Bessard, Choung Soo Kim, Lajos Géczi, Daniel Ford, Loïc Mourey, Joan Carles, Phillip Parente, Albert Font, Gabriel Kacso, Mustapha Chadjaa, Wenping Zhang, John Bernard, Johann de Bono
Journal: Journal of Clinical Oncology (2017)

Purpose Cabazitaxel 25 mg/m2 (C25) significantly improved overall survival (OS) versus mitoxantrone ( P < .001) in postdocetaxel patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase III TROPIC study. The phase III PROSELICA study ( ClinicalTrials.gov identifier: NCT01308580) assessed the noninferiority of cabazitaxel 20 mg/m2 (C20) versus C25 in postdocetaxel patients with mCRPC. Methods Patients were stratified by Eastern Cooperative Oncology Group performance status, measurability of disease per Response Evaluation Criteria in Solid Tumors (RECIST), and region, and randomly assigned to receive C20 or C25. To claim noninferiority of C20 (maintenance of ≥ 50% of the OS benefit of C25 v mitoxantrone in TROPIC) with 95% confidence level, the upper boundary of the CI of the hazard ratio (HR) for C20 versus C25 could not exceed 1.214 under a one-sided 98.89% CI after interim analyses. Secondary end points included progression-free survival, prostate-specific antigen (PSA), tumor and pain responses and progression, health-related quality of life, and safety. Results Overall, 1,200 patients were randomly assigned (C20, n = 598; C25, n = 602). Baseline characteristics were similar in both arms. Median OS was 13.4 months for C20 and 14.5 months for C25 (HR, 1.024). The upper boundary of the HR CI was 1.184 (less than the 1.214 noninferiority margin). Significant differences were observed in favor of C25 for PSA response (C20, 29.5%; C25, 42.9%; nominal P < .001) and time to PSA progression (median: C20, 5.7 months; C25, 6.8 months; HR for C20 v C25, 1.195; 95% CI, 1.025 to 1.393). Health-related quality of life did not differ between cohorts. Rates of grade 3 or 4 treatment-emergent adverse events were 39.7% for C20 and 54.5% for C25. Conclusion The efficacy of cabazitaxel in postdocetaxel patients with mCRPC was confirmed. The noninferiority end point was met; C20 maintained ≥ 50% of the OS benefit of C25 versus mitoxantrone in TROPIC. Secondary efficacy end points favored C25. Fewer adverse events were observed with C20.
Symptomatic dengue infection during pregnancy and the risk of stillbirth in Brazil, 2006–12: a matched case-control study
Authors: Enny S Paixão, Maria da Conceição N Costa, Maria Glória Teixeira, Katie Harron, Marcia Furquim de Almeida, Mauricio L Barreto, Laura C Rodrigues
Journal: The Lancet Infectious Diseases (2017)
Do donors matter? Short telomeres and survival after lung transplant
Authors: Emily S Clausen, Laurie D Snyder
Journal: Thorax (2017)

One of the great challenges of lung transplantation is the development of progressive small airway fibrosis leading to pulmonary function decline and allograft loss. Termed as chronic lung allograft dysfunction (CLAD), it is the leading cause of shortened long-term survival among lung transplant recipients and estimated to affect at least half of all recipients within 5 years after transplant.1 Risk factors for CLAD include type of transplant (single vs bilateral), infections, gastro-oesophageal reflux, graft ischaemic time, ischaemia–reperfusion injury, air pollution exposure, acute cellular rejection (ACR) episodes and specific antibody development.2 In this issue of Thorax , Faust and colleagues propose a new risk factor for CLAD: short donor telomere length (TL).3 

Telomeres consist of repetitive DNA sequences bound to shelterin protein complex at chromosome ends to provide protection from degradation during cell division. Short TL has been identified as a major contributor to lung disease, most notably as a genetic mediator of a subset of patients with idiopathic pulmonary fibrosis (IPF). In particular, mutations in multiple telomere-related genes that code for components of the telomerase enzyme complex are known to be associated with familial idiopathic interstitial pneumonia (IIP), as well as a smaller subset of patients with sporadic …
What End Users and Stakeholders Want From Automated Insulin Delivery Systems
Authors: Diana Naranjo, Sakinah C. Suttiratana, Esti Iturralde, Katharine D. Barnard, Jill Weissberg-Benchell, Lori Laffel, Korey K. Hood
Journal: Diabetes Care (2017)

OBJECTIVE The purpose of this study was to rigorously explore psychosocial factors associated with automated insulin delivery systems among people living with type 1 diabetes. RESEARCH DESIGN AND METHODS Across four sites in the U.S. and U.K., 284 participants completed structured interviews or focus groups on expectations, desired features, potential benefits, and perceived burdens of automated insulin delivery systems. Recorded audio files were transcribed and analyzed using NVivo. RESULTS Three themes were identified as critical for uptake of automated insulin delivery: considerations of trust and control, system features, and concerns and barriers to adoption. Children and adolescents with type 1 diabetes primarily identified needs specific to their life stage and social contexts (e.g., school). Adults with type 1 diabetes, parents of youth with type 1 diabetes, and partners of adults with type 1 diabetes were most concerned about the accuracy, adaptability, and algorithm quality alongside expectations that systems stabilize glucose levels and reduce risk for long-term complications. CONCLUSIONS Incorporating stakeholder perspectives on use of automated insulin delivery systems will improve the adoption of devices, quality of life, and likelihood of optimal health. Efforts to build trust in systems, optimize user-system interactions, and provide clear guidance about device capabilities and limitations may help potential users achieve optimal glycemic outcomes.
Diagnosis of Infective Endocarditis After TAVR
Authors: Erwan Salaun, Laura Sportouch, Pierre-Antoine Barral, Sandrine Hubert, Cécile Lavoute, Anne-Claire Casalta, Julie Pradier, Daniel Ouk, Jean-Paul Casalta, Marc Lambert, Frédérique Gouriet, Jean-Yves Gaubert, Aurélie Dehaene, Alexis Jacquier, Laetitia Tessonnier, Julie Haentjens, Alexis Theron, Alberto Riberi, Serge Cammilleri, Dominique Grisoli, Nicolas Jaussaud, Frédéric Collart, Jean-Louis Bonnet, Laurence Camoin, Sebastien Renard, Thomas Cuisset, Jean-François Avierinos, Hubert Lepidi, Olivier Mundler, Didier Raoult, Gilbert Habib
Journal: JACC. Cardiovascular imaging (2017)
Changing the Discussion about On-Pump versus Off-Pump CABG
Authors: Eugene H. Blackstone, Joseph F. Sabik
Journal: New England Journal of Medicine (2017)

The performance of coronary-artery bypass grafting (CABG) without the use of the heart–lung machine (pump) was introduced to avoid the damaging effects of cardiopulmonary bypass.1 On-pump CABG with cardiopulmonary bypass is generally performed on an arrested heart, and off-pump CABG on a beating heart, without cardiopulmonary bypass. Off-pump CABG became popular in the 1990s, peaking at just under 25% of the CABG operations performed in the United States in 2002; the rate then plateaued and has been slowly declining. Some surgeons remain enthusiasts, whereas others have never attempted it; many use it selectively.2,3 Controversy over the value of off-pump CABG . . .
Aberrant STAT3 Ser727 phosphorylation and Its association with negative estrogen receptor status in breast infiltrating ductal carcinoma
Authors: Sujeeve Jeganathan, Anahita Amiri, Thomas D. Wu, Jonathan Lee
Journal: Cancer Research (2005)

3699    Purpose:  Phosphorylation in serine residue 727 is able to modulate the transcriptional activity of STAT3. However, the role of STAT3 serine phosphorylation in breast cancer is mostly unexplored. In this study, we analyzed the expression patterns of serine residue 727-phosphorylated STAT3 (p-ser727-STAT3) in breast cancer and correlated its expression profiles with clinicopathological parameters.  Experimental Design:  Immunoblotting and immunohistochemistry techniques, using antibodies against p-ser727-STAT3 and STAT3, respectively, were applied on 48 pairs of breast infiltrating ductal carcinoma tissues and its nearby noncancer breast tissues. The results were then analyzed for their significance by multivariate analyses.  Results : Significantly elevated p-ser727-STAT3 expression, after normalization by total STAT3 protein, was observed in 60.4 % (29/48) of the breast cancer tissues, in comparison to the matched noncancer breast tissues ( P  P  = 0.027, 0.031, and 0.005 individually). Intriguingly, we noticed that the expression levels of p-ser727-STAT3 in ER-negative breast cancer cell lines (MDA-MB-231, SKBR-3 and MDA-MB-468) were higher than that in ER-positive breast cancer cell lines (MCF-7, ZR75-1 and T47D) and the immortalized breast epithelial cell line (MCF-10A). On the other hand, treatment with ERα-specific siRNA or anti-breast cancer drug tamoxifen increased the expression of p-ser727-STAT3 in MCF-7 cells, but not ER-negative MDA-MB-231 cells, in a dose-dependent manner.  Conclusions:  Our results suggested a possible involvement of p-ser727-STAT3 in the pathogenesis of breast cancer. Besides, p-ser727-STAT3 status may serve as a prognostic factor for breast cancer.
[<sup>18</sup>F]FMAU for PET imaging in breast cancer patients.
Authors: Peter Conti, Kai Chen, Debu Tripathy, Hossein Jadvar
Journal: Journal of Clinical Oncology (2015)

11056 Background: To develop a practicable method of synthesizing 18F-labeled 2’-deoxy-2’-fluour-5-methyl-1-β-D-arabinofuranosyluracil ([18F]FMAU) for clinical investigation and study [18F]FMAU in patients with known breast cancer to obtain data on safety, circulating metabolite, tumor imaging feasibility, and radiation dosimetry. Methods: Various reaction factors, such as time, temperature, and solvent effect, were explored to optimize [18F]FMAU synthesis. A total of nine breast cancer patients were scanned. [18F]FMAU, 10 mCi i.v. injection in saline was administered to the patient through venous line. Multi-bed position PET scans over tumor-bearing region(s) were obtained, along with attenuation correction images, throughout the time period between 1 and 120 minutes post injection. Throughout the procedure, study staff monitored and recorded patient vital signs. Results: A simplified synthesis of [18F]FMAU with shorter synthesis time and higher radiochemical yield was achieved as compared to previously reported methods. The total synthesis time was about 90 min from the end of bombardment.Radiochemical purity was > 99% and specific activity was > 400 mCi/μmol. The PET imaging showed excellent primary breast tumor as well as metastatic disease uptake of [18F]FMAU. No adverse reactions were observed for all studied patients. No major circulating metabolites were identified in human blood at 1 h post injection of [18F]FMAU. The preliminary dosimetry of [18F]FMAU was estimated as 5.0 rem in liver (primary organ), 4.2 rem in kidneys (secondary organ), 0.76 rem in whole body, 0.60 rem in active blood forming organs, and 0.45 rem in gonads per single administration. Conclusions: A simplified one-pot synthesis of [18F]FMAU has been developed, which is well suitable for clinical investigations. Our pilot trial achieved its goals of obtaining data on safety, circulating metabolite, breast tumor imaging feasibility, and radiation dosimetry of [18F]FMAU in humans. The data provided a solid foundation for proceeding to larger clinical trials to confirm the utility of [18F]FMAU as an in vivo cell proliferation marker for non-invasively and serially estimating DNA synthesis in patients with cancer.
Neurodevelopmental Outcome in Relation to Treatment of Patent Ductus Arteriosus
Authors: Viola Christmann, Nel Roeleveld, Arno F. J. van Heijst
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial
Authors: A. Tsianakas, T.A. Luger, A. Radin
Journal: British Journal of Dermatology (2017)

Dupilumab, a human anti-interleukin-4 receptor alpha monoclonal antibody, significantly improved clinical signs and symptoms in adults with moderate-to-severe atopic dermatitis in a randomized, double-blind, placebo-controlled, phase IIa trial.We evaluate health-related quality of life (HRQoL) and correlation of HRQoL with secondary clinical and patient-reported outcomes in a subset of patients from this trial of dupilumab.Patients were randomized to 300 mg weekly subcutaneous dupilumab or placebo for 12 weeks (trial registration: NCT01548404). The Quality of Life Index of Atopic Dermatitis (QoLIAD) score (exploratory outcome) and its correlation with efficacy outcomes [Eczema Area and Severity Index (EASI); primary end point; SCORing Atopic Dermatitis (SCORAD), SCORAD visual analogue scale (VAS) scores for sleep and pruritus, pruritus numerical rating scale (NRS) and 5-dimensional pruritus] were assessed in 64 adults with moderate-to-severe atopic dermatitis.Mean QoLIAD scores at baseline ± standard error (SE) were 13·3 ± 1·34 and 11·3 ± 1·09 for the placebo and dupilumab groups, respectively. Dupilumab significantly improved QoLIAD score after 12 weeks of treatment vs. placebo (mean % change from baseline in QoLIAD score ± SE: -64·0 ± 6·91 vs. -11·1 ± 9·31). Least squares mean % difference from baseline vs. placebo in QoLIAD score ±SE was -52·0 ± 11·43, P < 0·001). QoLIAD scores significantly correlated with changes in efficacy outcomes, including EASI (r = 0·44), 5-dimensional pruritus (r = 0·49), pruritus NRS (r = 0·41), total SCORAD (r = 0·56) and SCORAD VAS scores for sleep (r = 0·47) and pruritus (r = 0·54); all P < 0·05.Dupilumab improved QoLIAD scores in adults with atopic dermatitis and was significantly associated with improvements in study outcomes.
脂質異常症におけるDNAメチル化の役割:系統的レビュー【Powered by NICT】
Authors: V E Braun Kim, Voortman Trudy, Dhana Klodian, Troup Jenna, M Bramer Wichor, Troup John, Chowdhury Rajiv, Dehghan Abbas, Muka Taulant, H Franco Oscar
Journal: Progress in Lipid Research (2016)
CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL.
Authors: Saar Gill, Noelle V. Frey, Elizabeth O. Hexner, Simon F. Lacey, Jan Joseph Melenhorst, John C. Byrd, Susan Metzger, Taylor Marcus, Whitney Gladney, Katherine Marcucci, Wei-Ting Hwang, Carl H. June, David L. Porter
Journal: Journal of Clinical Oncology (2017)

7509 Background: Immunotherapy with anti-CD19 CART cells induces complete remission (CR) in the minority of patients with CLL, but where CRs occur they tend to be durable. Based on preclinical evidence of synergy, we combined anti-CD19 CAR T cells with ibrutinib to test the hypothesis that pre- and concurrent treatment would enhance the CR rate. Methods: This is a pilot trial of anti-CD19 CAR T cells in adults with CLL/SLL who were not in CR despite at least 6 months of ibrutinib. Pts must have failed at least 1 regimen before ibrutinib, unless they had del(17)(p13.1) or a TP53 mutation. T cells were lentivirally transduced to express a CAR comprising CD3z, 4-1BB, and humanized anti-CD19 scFv (CTL119). Pts were lymphodepleted 1 week before infusion. Ibrutinib was continued throughout the trial. Results: Manufacturing was successful in all pts. Ten pts (9M, 1F; ages 47-77; 0-12 regimens prior to ibrutinib) have been infused. All had abnormalities of TP53 or ATM and two pts had increasing BTK C481S clones. Median marrow CLL burden was 10% (range 10-50%). The median follow-up is 6 months (range 0.5-9). Cytokine release syndrome (CRS) developed in 9 pts; gr1 in 2, gr2 in 6 and gr3 in 1 pt. One pt developed gr4 tumor lysis syndrome. Treatment of CRS with the IL-6 receptor antagonist tocilizumab was not required. At 3 months, 8 evaluable pts had achieved an MRD-ve marrow CR (89%) by 9-color flow, and all remain in marrow CR at last F/U. There was modest residual splenomegaly in 3/5 patients, and adenopathy resolved in 4/6 subjects with progression in 1/6. MRD assessment by deep sequencing will be presented. Conclusions: We observed 89% MRD-ve marrow CR in pts with high-risk CLL using a well-tolerated combination of CART cells and ibrutinib. Longer follow-up will reveal the durability of these results and could support evaluation of a first-line combination approach in an attempt to obviate the need for chronic therapy. Clinical trial information: NCT02640209.
Development and implementation of a multidisciplinary geriatric oncology (GO) clinic in Mexico.
Authors: Enrique Soto Perez De Celis, Ana Patricia Navarrete Reyes, Odin Vazquez Valdez, Nora Ivonne Reyes Martinez, Jose de Jesus Ruiz Lopez, Juan Miguel Antonio Garcia Lara, Jose Alberto Avila Funes
Journal: Journal of Clinical Oncology (2016)

e21519 Background: Cancer is an age related disease, and the number of older cancer patients will rise dramatically in the next decades. This will be proportionally higher for developing countries like Mexico, where 25% of the population will be ≥ 60 years by 2050. Although GO clinics have been implemented in developed nations, few have been created in developing countries. Here we report on the development and implementation of the first GO clinic in Mexico. Methods: Our objective was to develop a multidisciplinary GO clinic in a public teaching hospital in Mexico City. Patients aged ≥ 70 years are referred to our clinic before staring treatment and screened using the validated G8 geriatric assessment tool. Those considered to be potentially vulnerable are referred for a full comprehensive geriatric assessment (CGA), which is undertaken by a multidisciplinary team including a medical oncologist, a geriatrician, a nutritionist and a physical therapist during a single clinic visit. Patients are classified as fit, vulnerable or frail according to CGA results. Fit patients are referred back to their oncologists, while vulnerable patients undergo follow up at our clinic in order to create an individualized therapeutic plan. Patients deemed unsuitable for treatment receive follow up by a geriatrician specialized in palliative care. Results: 70 patients with an average age of 74 years were seen during the clinic's first 7 months. The most common diagnoses were genitourinary malignancies (36%) followed by gastrointestinal (27%), breast (12%) and lung cancer (12%). After screening, 45% of the patients were determined to be fit and 55% were classified as vulnerable/frail and were referred for full assessment. 32% had moderate to severe physical performance limitations and 19% had abnormal cognitive screening tests. Patients reported a high level of satisfaction with the clinic. Conclusions: We have successfully established the first comprehensive GO clinic in Mexico. In developing countries facing population aging, multidisciplinary patient-centered models of care like the one we propose, in which different specialties work together, are needed in order to improve the quality of care and the outcomes of older adults with cancer.
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: an updated meta-analysis
Authors: Catherine M Olsen, Adele C Green
Journal: Annals of the Rheumatic Diseases (2017)

We read with interest the report by Mercer et al in the February 2017 issue of ARD 1 which examined the risk of invasive melanoma in patients with rheumatoid arthritis (RA) treated with biologics. In a collaborative analysis of data from nine European countries (11 biologics registers), the authors report a pooled standardised incidence ratio (SIR) for tumour necrosis factor inhibitor (TNFi)-exposed patients of 1.2 (95% CI 0.99 to 1.6) compared with the general population (country specific) and an incidence rate ratio (IRR) of 1.1 (0.8–1.6) for TNFi-exposed patients compared with biologic naive patients. While they allowed that an increased melanoma risk in patients with RA treated with TNFi could not …
Water Exchange to Facilitate Unsedated Colonoscopy—Reply
Authors: Felix W. Leung
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal